{"commentary":{"count":51,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":26,"youtube":13,"podcast":11,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05052801\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"FORTITUDE-101","nct_id":"NCT05052801","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=fortitude-101-nct05052801. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"FORTITUDE-101","arms":[{"description":null,"label":"Bemarituzumab with mFOLFOX6","type":"EXPERIMENTAL"},{"description":null,"label":"Placebo with mFOLFOX6","type":"ACTIVE_COMPARATOR"}],"collaborators":["Zai Lab (China only)"],"completion_date":{"date":"2026-04-26","type":"ACTUAL"},"conditions":["Gastric Cancer","Gastroesophageal Junction Adenocarcinoma"],"enrollment":{"count":547,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Bemarituzumab","type":"DRUG"},{"name":"mFOLFOX6","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"last_update":"2026-05-27","lead_sponsor":"Amgen","official_title":"A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2025-06-20","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival","timeFrame":"Up to approximately 3.5 years"}],"references":[{"citation":"Rha SY, Zhang Y, Elme A, Pazo Cid R, Alacacioglu A, Ziogas DC, Shitara K, Ranceva A, Nemecek R, Santoro A, Calderon CA, Korphaisarn K, Davis T, Zahlten-Kuemeli A, Conn C, Tan M, Honeycutt H, Wainberg ZA. Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial. JCO Precis Oncol. 2025 Jan;9:e2400710. doi: 10.1200/PO-24-00710. Epub 2025 Jan 24.","pmid":"39854659","type":"BACKGROUND"},{"citation":"Farooq AV, Kaur S, Hundal P, Burke M, Sulaiman R, Zahlten-Kumeli A, Raoof S, Li Z, Murias Dos Santos T, Huang XJ, Colby K. Advancing Ocular Safety Profile Assessment: A Novel Grading Scale for Ocular Adverse Reactions Associated with Bemarituzumab. Ophthalmol Ther. 2025 Jul;14(7):1349-1356. doi: 10.1007/s40123-025-01139-6. Epub 2025 May 12.","pmid":"40355729","type":"BACKGROUND"},{"citation":"Yu J, Mehta R. Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma. J Natl Compr Canc Netw. 2025 May;23(5):e257036. doi: 10.6004/jnccn.2025.7036.","pmid":"40341124","type":"DERIVED"},{"citation":"Wainberg ZA, Kang YK, Lee KW, Qin S, Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, Teixeira A, Hitre E, Udrea AA, Cardellino GG, Sanchez RG, Zahlten-Kumeli A, Taylor K, Enzinger PC. Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial. Gastric Cancer. 2024 May;27(3):558-570. doi: 10.1007/s10120-024-01466-w. Epub 2024 Feb 3.","pmid":"38308771","type":"DERIVED"}],"start_date":{"date":"2022-03-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression","url":"https://clinicaltrials.gov/study/NCT05052801"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/fortitude-101-nct05052801"}